Press coverage about Mast Therapeutics (NASDAQ:SVRA) has trended somewhat positive on Tuesday, according to Accern. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Mast Therapeutics earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.18319876195 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

A number of research firms have recently issued reports on SVRA. Canaccord Genuity reiterated a “buy” rating and set a $18.00 price objective on shares of Mast Therapeutics in a research note on Monday, July 17th. Zacks Investment Research lowered shares of Mast Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, September 15th. Roth Capital reiterated a “buy” rating and set a $40.00 price objective on shares of Mast Therapeutics in a research note on Wednesday, September 27th. Finally, Jefferies Group LLC began coverage on shares of Mast Therapeutics in a research note on Friday, September 22nd. They set a “buy” rating and a $20.00 price objective on the stock. Five analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus target price of $21.30.

Mast Therapeutics (SVRA) traded up $0.02 during mid-day trading on Tuesday, hitting $9.34. 55,810 shares of the stock were exchanged, compared to its average volume of 120,507. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.83 and a quick ratio of 7.83. Mast Therapeutics has a twelve month low of $4.60 and a twelve month high of $16.23.

In other news, Director Yuri Pikover acquired 50,000 shares of the business’s stock in a transaction on Friday, October 27th. The stock was bought at an average price of $7.85 per share, with a total value of $392,500.00. Following the completion of the acquisition, the director now owns 150,000 shares of the company’s stock, valued at $1,177,500. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.93% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: This piece was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at

Mast Therapeutics Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Insider Buying and Selling by Quarter for Mast Therapeutics (NASDAQ:SVRA)

Receive News & Ratings for Mast Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.